Cargando…
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performed RNA sequencing (n = 97) and multiplexed immunofluorescence...
Autores principales: | Zhou, Xu, An, Jingyu, Kurilov, Roma, Brors, Benedikt, Hu, Kai, Peccerella, Teresa, Roessler, Stephanie, Pfütze, Katrin, Schulz, Angela, Wolf, Stephan, Hohmann, Nicolas, Theile, Dirk, Sauter, Max, Burhenne, Jürgen, Ei, Shigenori, Heger, Ulrike, Strobel, Oliver, Barry, Simon T., Springfeld, Christoph, Tjaden, Christine, Bergmann, Frank, Büchler, Markus, Hackert, Thilo, Fortunato, Franco, Neoptolemos, John P., Bailey, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518256/ https://www.ncbi.nlm.nih.gov/pubmed/37679568 http://dx.doi.org/10.1038/s43018-023-00628-6 |
Ejemplares similares
-
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
por: Zhou, Xu, et al.
Publicado: (2021) -
Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer
por: Zhou, Xu, et al.
Publicado: (2023) -
Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
por: Bailey, Peter, et al.
Publicado: (2023) -
Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival
por: Tjaden, Christine, et al.
Publicado: (2023) -
Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019)